Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Innate Pharma SA (IPHYF : OTC)

• Company Description    Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. Number of Employees: 181

• Price / Volume Information    Yesterday's Closing Price: $1.31 Daily Weekly Monthly 20 Day Moving Average: 38 shares Shares Outstanding: 83.83 (millions) Market Capitalization: $109.82 (millions) Beta: 0.50 52 Week High: $2.90 52 Week Low: $1.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.50% -27.32% 12 Week -9.66% -24.01% Year To Date -54.83% -57.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 AVENUE DE LUMINY BP 30191 - MARSEILLE,I0 13009 FRA ph: 33-4-30-30-30-30 fax: 33-04-30-30-30-00 investors@innate-pharma.fr http://www.innate-pharma.com

• General Corporate Information    Officers Mondher Mahjoubi - Chief Executive Officer and Chairman Herve Brailly - Chairman Irina Staatz-Granzer - Vice Chairman Frederic Lombard - Chief Financial Officer Yannis Morel - Executive Vice President Peer Information Innate Pharma SA (GSAC) Innate Pharma SA (CASI) Innate Pharma SA (ALCD.) Innate Pharma SA (OMNN) Innate Pharma SA (CGPI.) Innate Pharma SA (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: F5277D100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 83.83 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $109.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 11.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 2.60 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 2.60 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -245.87 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.11 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©